Incretin concepts.
Bloomgarden
Zachary T
ZT
Division of Endocrinology, Mount Sinai School of Medicine, New York, New York, USA.
D002316:Cardiotonic Agents / Q000627:therapeutic use; D048909:Diabetes Complications / Q000503:physiopathology; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D054795:Incretins / Q000502:physiology*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D000069450:Liraglutide; D017202:Myocardial Ischemia / Q000188:drug therapy; D010455:Peptides / Q000502:physiology / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D002316:Cardiotonic Agents; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D010455:Peptides; D014688:Venoms; C114437:glucagon-like peptide-1 (9-36)-amide; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide